The effects of psychotropic drugs on the regulation of glucose metabolism

Current Diabetes Reviews

Volumn 9, Issue 5, 2013, Pages 362-370

  Al Zoairy, Ramona ^a   Ress, Claudia ^a   Tschoner, Alexander ^a   Kaser, Susanne ^a   Ebenbichler, Christoph ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Antidepressants; Antipsychotics; Diabetes; Glucose metabolism; Insulin resistance; Psychotropic drugs; Weight gain

Indexed keywords

AMFEBUTAMONE; AMISULPRIDE; AMITRIPTYLINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOZAPINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; GLUCOSE; HALOPERIDOL; METFORMIN; MIRTAZAPINE; MOCLOBEMIDE; NALTREXONE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PHENELZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTRALINE; TRANYLCYPROMINE; VENLAFAXINE; ZIPRASIDONE;

BLOOD PRESSURE; BODY MASS; BODY WEIGHT; DIABETES MELLITUS; DIET RESTRICTION; DRUG EFFECT; DYSLIPIDEMIA; DYSTONIA; EATING HABIT; FAMILY HISTORY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HALLUCINATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MOTION; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PARKINSON DISEASE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SMOKING; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; CARBOHYDRATE METABOLISM; GLUCOSE; HUMANS; META-ANALYSIS AS TOPIC; PSYCHOTROPIC DRUGS; SIGNAL TRANSDUCTION; WEIGHT GAIN;

EID: 84882779680     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/15733998113099990067     Document Type: Review

References (115)

1. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA. 2007; 298(15): 1794-1796.
2. Jin H, Folsom D, Sasaki A, et al. Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms. Schizophr Res. 2011; 125(2-3): 295-299.
3. Kahl KG. [The metabolic syndrome and mental illness: relevance, risk factors and practical consequences.] MMW Fortschr Med. 2005; 147(42): 32-34, 36.
4. Gracious BL, Cook SR, Meyer AE, et al., Prevalence of overweight and obesity in adolescents with severe mental illness: a cross-sectional chart review. J Clin Psychiatry. 2010; 71(7): 949-954.
5. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010; 71(10): 1259-1272.
6. Tschoner A, Engl J, Laimer M, et al., Metabolic side effects of antipsychotic medication. Int J Clin Pract. 2007; 61(8): 1356-1370.
7. Haslam DW, James WP. Obesity. Lancet. 2005; 366(9492): 1197-1209.
8. Nuevo R, Chatterji S, Fraguas D, et al., Increased risk of diabetes mellitus among persons with psychotic symptoms: results from the WHO World Health Survey. J Clin Psychiatry. 2011; 72(12): p. 1592-1599.
9. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care. 2004; 27(2): 596-601
10. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001; 62 Suppl 7: 22-31.
11. Coodin S. Body mass index in persons with schizophrenia. Can J Psychiatry. 2001; 46(6): 549-555.
12. Ader M, Kim SP, Catalano KJ, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs.Diabetes Care. 2005; 54(3): 862-871.
13. Engl J, Tschoner A, Laimer M, et al. [Antipsychotic drug-induced changes in metabolism]. Wien Klin Wochenschr. 2006; 118(7-8): 196-206.
14. Ramankutty G. Olanzapine-induced destabilization of diabetes in the absence of weight gain. Acta Psychiatr Scand. 2002; 105(3): 235-236; discussion 236-7.
15. Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res. 2005; 79(2-3): 145-155.
16. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002; 22: 841-852.
17. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010; (3): CD006654.
18. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12): 1209-1223.
19. Eder U, Mangweth B, Ebenbichler C, et al. Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry. 2001; 158(10): 1719-1722.
20. Engl J, Laimer M, Niederwanger A, et al. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry. 2005; 10(12): 1089-1096.
21. Ebenbichler CF, Laimer M, Eder U, et al. Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry. 2003; 64(12): 1436-1439.
22. Tschoner A, Engl J, Rettenbacher M, et al. Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study. Pharmacopsychiatry. 2009; 42(1): 29-34.
23. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf. 2001; 24(1): 59-73.
24. Chen da C, Zhou MA, Zhou DH, et al. Gender differences in the prevalence of diabetes mellitus in chronic hospitalized patients with schizophrenia on long-term antipsychotics. Psychiatry Res. 2011; 186(2-3): 451-453.
25. Avram AM, Patel V, Taylor HC, et al. Euglycemic clamp study in clozapine-induced diabetic ketoacidosis. Ann Pharmacother. 2001; 35(11): 1381-1387.
26. Kessing LV, Thomsen AF, Mogensen UB, et al. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry. 2010; 197(4): 266-671.
27. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002; 59(11): 1021-1206.
28. Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008; 105(1-3): 175-187.
29. Parsons B, Allison DB, Loebel A, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res. 2009; 110(1-3): 103-110.
30. Church CO, Stevens DL, Fugate SE. Diabetic ketoacidosis associated with aripiprazole. Diabet Med. 2005; 22(10): 1440-1443.
31. Reddymasu S, Bahta E, Levine S, et al. Elevated lipase and diabetic ketoacidosis associated with aripiprazole. JOP. 2006; 7(3): 303-305.
32. Kibbey KJ, Roberts AM, Nicholson GC. Diabetic ketoacidosis and elevated serum lipase in the setting of aripiprazole therapy. Diabetes Care. 2010; 33(7): e96.
33. Peuskens J, De Hert M, Mortimer A, et al. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int Clin Psychopharmacol. 2007; 22(3): 145-152.
34. Blonde L, Kan HJ, Gutterman EM, et al. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. J Clin Psychiatry. 2008; 69(5): 741-748.
35. Roix JJ, DeCrescenzo GA, Cheung PH, et al. Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretion. Diabetes Obes Metab. 2011; 14(4):329-334
36. Yood MU, DeLorenze G, Quesenberry CP Jr, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent-results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf. 2009; 18(9): 791-799.
37. Meyer JM, Davis VG, McEvoy JP, et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res. 2008; 103(1-3): 104-109.
38. McIntyre RS, Cragin L, Sorensen S, et al. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. J Eval Clin Pract. 2010; 16(4): 744-755.
39. Bushe CJ, Leonard BE. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J Clin Psychiatry. 2007; 68(11): 1682-1690.
40. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006; 86(1-3): 15-22.
41. De Hert M, Schreurs V, Sweers K, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res.2008; 101(1-3): 295-303.
42. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Molecular Psychiatry. 2008; 13: 27-35.
43. Leibowitz SF, Alexander JT. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psychiatry. 1998; 44(9): 851-864.
44. Leibowitz SF. The role of serotonin in eating disorders. Drugs. 1990; 39(3): 33-48.
45. Guillet-Deniau I, Burnol AF, Girard J. Identification and Localization of a Skeletal Muscle Secrotonin 5-HT2A Receptor Coupled to the Jak/STAT Pathway. The Journal of Biological Chemistry. 1997; 272(23): 14825-14829.
46. Ujike H, Nomura A, Morita Y, et al. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry. 2008; 69(9): 1416-1422.
47. Kring SI, Werge T, Holst C, et al. Polymorphisms of serotonin receptor 2A and 2C genes and COMT in relation to obesity and type 2 diabetes. PLoS One. 2009; 4(8): e6696.
48. Melkersson KI, Gunes A, Dahl ML. Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in clozapine-and olanzapinetreated patients. Hum Psychopharmacol. 2010; 25(4): 347-352.
49. Paulmann N, Grohmann M, Voigt JP, et al. Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation. PLoS Biol. 2009; 7(10): e1000229
50. Nonogaki K, Strack AM, Dallman MF, et al. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med. 1998; 4(10): 1152-1156.
51. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. Pharmacol Ther. 2010; 125(1): 169-179.
52. Garcia-Tornadú I, Perez-Millan MI, Recouvreux V, et al. New insights into the endocrine and metabolic roles of dopamine D2 receptors gained from the Drd2 mouse. Neuroendocrinology. 2010; 92(4): 207-214.
53. Lencz T, Robinson DG, Napolitano B, et al. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics. 2010; 20(9): 569-572.
54. Mueller DJ, Zai CC, Sicard M. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J. 2010; 12(2): 156-64
55. Ratliff JC, Barber JA, Palmese LB, et al. Association of prescription H1 antihistamine use with obesity: results from the National Health and Nutrition Examination Survey. Obesity (Silver Spring). 2010; 18(12): 2398-2400.
56. Han M, Deng C, Burne TH, et al. Short-and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology. 2008; 33(5): 569-580.
57. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003; 28(3): 519-526.
58. Arrang JM. Histamine and schizophrenia. Int Rev Neurobiol. 2007; 78: 247-287.
59. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature, 1998. 395(6704): 763-770.
60. Laimer M, Ebenbichler C, Kranebitter M, et al. Olanzapineinduced hyperglycemia: role of humoral insulin resistance-inducing factors. J Clin Psychopharmacol. 2005;25(2): 183-185.
61. Melkersson KI, Hulting AL. Insulin and leptin levels in patients with schizophrenia or related psychoses--a comparison between different antipsychotic agents. Psychopharmacology. 2001; 154(2): 205-212.
62. Venkatasubramanian G, Chittiprol S, Neelakantachar N, et al. A longitudinal study on the impact of antipsychotic treatment on serum leptin in schizophrenia. Clin Neuropharmacol. 2010; 33(6): 288-292.
63. Calarge CA, Ellingrod VL, Zimmerman B, et al. Leptin gene - 2548G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatr Genet. 2009; 19(6): 320-327.
64. Perez-Iglesias R, Mata I, Amado JA, et al. Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with antipsychotic treatment. J Clin Psychopharmaco. 2010; 30(6): 661-666.
65. Perez-Iglesias R, Mata I, Amado JA, et al. Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. Pharmacogenomics. 2010; 11(6): 773-780.
66. Haack M, Hinze-Selch D, Fenzel T, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res. 1999; 33(5): 407-418.
67. Pollmächer T, Hinze-Selch D, Mullington J., Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol. 1996; 16(5): p. 403-409.
68. Tschoner A, Fleischhacker WW, Ebenbichler CF. Experimental antipsychotics and metabolic adverse effects-findings from clinical trials. Curr Opin Investig Drugs. 2009; 10(10): 1041-1048.
69. De Hert M, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009; 24(6): 412-424.
70. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry.2009; 66(8): 848-856.
71. Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001; 24(6): 1069-1078.
72. Toplak H, Abrahamian H. Impact of depression on diabetes mellitus. Obes Facts. 2009; 2(4): 211-215.
73. Ress C, Tschoner A, Kaser S, et al. [Psychotropic drugs and diabetes.]. Wien Med Wochenschr. 2011; 162(23-24): 541-542
74. Hennings JM, Ising M, Grautoff S, et al. Glucose tolerance in depressed inpatients, under treatment with mirtazapine and in healthy controls. Exp Clin Endocrinol Diabetes. 2010; 118(2): 98-100.
75. Andersohn F, Schade R, Suissa S, et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009; 166: 591-598.
76. Rubin RR, Ma Y, Marrero DG, et al. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetesduring the diabetes prevention program. Diabetes Care. 2008; 31: 420-426.
77. Knol MJ, Geerlings MI, Egberts AC, et al. No increased incidence of diabetes in antidepressant users. Int Clin Psychopharmacol. 2007; 22: 382-386.
78. Knol MJ, Derijks HJ, Geerlings MI, et al. Influence of antidepressants on glycaemic control in patients with diabetes mellitus. Pharmacoepidemiol Drug Saf. 2008; 17(6): 577-586.
79. Kivimäki M, Hamer M, Batty GD, et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes Care. 2010; 33(12): 2611-2616.
80. Buhl ES, Jensen TK, Jessen N, et al. Treatment with an SSRI antidepressant restores hippocampo-hypothalamic corticosteroid feedback and reverses insulin resistance in low-birth-weight rats. Am J Physiol Endocrinol Metab, 2010; 298(5): E920-9
81. Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry.2001; 13(1): 31-41.
82. McIntyre RS, Soczynska JK, Konarski JZ, et al. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf. 2006; 5(1): 157-168.
83. Kopf D, Westphal S, Luley CW, et al. Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. J Clin Psychopharmacol. 2004; 24(5): 527-531.
84. Abrahamian H, Hofmann P, Prager R, et al. Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group). Neuropsychiatr Dis Treat. 2009; 5: 261-266.
85. Potter van Loon BJ, Radder JK, Frölich M, et al. Fluoxetine increases insulin action in obese nondiabetic and in obese noninsulindependent diabetic individuals. Int J Obes Relat Metab Disord. 1992; 16(2): 79-85.
86. Gray DS, Fujioka K, Devine W, et al. A randomized double-blind clinical trial of fluoxetine in obese diabetics. Int J Obes Relat Metab Disord. 1992; 16 Suppl 4: S67-72.
87. Maheux P, Ducros F, Bourque J, et al. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord. 1997; 21(2): 97-102.
88. Dastjerdi MS, Kazemi F, Najafian A, et al. An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction. Int J Obes (Lond). 2007; 31(4): 713-717.
89. Lawrence J, Current Clinical Strategies Pub. Handbook of psychiatric drugs, 1998.
90. Doogan DP. Toleration and safety of sertraline: experience worldwide. Int Clin Psychopharmacol. 1991; 6 Suppl 2: 47-56.
91. Harrison CL, Ferrier N, Young AH. Tolerability of high-dose venlafaxine in depressed patients. J Psychopharmacol. 2004; 18(2): 200-204.
92. Kraus T, Haack M, Schuld A, et al. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry, 2002; 35(6): 220-225.
93. Rudolph RL, Fabre LF, Feighner JP, et al. A randomized, placebocontrolled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry. 1998; 59(3): 116-122.
94. Raeder MB, Bjelland I, Emil Vollset S, et al. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J Clin Psychiatry. 2006; 67(12): 1974-1982.
95. Xiong GL, Jiang W, Clare R, et al. Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting. Am J Cardiol. 2006; 98(1): 42-47.
96. Laimer M, Kramer-Reinstadler K, Rauchenzauner M, et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry. 2006; 67(3): 421-424.
97. Himmerich H, Fulda S, Schaaf L, et al. Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care. 2006; 29(1): 170.
98. Chiu HW, Li TC. Rapid weight gain during mirtazapine treatment. J Neuropsychiatry Clin Neurosci. 2011;. 23(1): E7.
99. Fisfalen ME, Hsiung RC. Glucose dysregulation and mirtazapineinduced weight gain. Am J Psychiatry. 2003; 160(4): 797.
100. Lustman PJ, Williams MM, Sayuk GS, et al. Factors influencing glycemic control in type 2 diabetes during acute-and maintenancephase treatment of major depressive disorder with bupropion. Diabetes Care. 2007; 30(3): 459-466.
101. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebocontrolled, phase 3 trial. Lancet. 2010; 376(9741): 595-605.
102. Katsiki N, Hatzitolios AI, Mikhailidis DP. Naltrexone sustainedrelease (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? Ann Med. 2011; 43(4): 249-258.
103. Dryden S, Frankish HM, Wang Q, et al. The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats. Neuroscience. 1996; 72(2): 557-566.
104. Gutiérrez A, Saracíbar G, Casis L, et al. Effects of fluoxetine administration on neuropeptide y and orexins in obese zucker rat hypothalamus. Obes Res. 2002; 10(6): 532-540.
105. Myung CS, Kim BT, Choi SH, et al. Role of neuropeptide Y and proopiomelanocortin in fluoxetine-induced anorexia. Arch Pharm Res. 2005;. 28(6): 716-721.
106. Kalra SP, Kalra PS, Neuropeptide Y.: a physiological orexigen modulated by the feedback action of ghrelin and leptin. Endocrine. 2003; 22(1): 49-56.
107. Nguyen AD, Herzog H, Sainsbury A., Neuropeptide Y and Peptide YY: Important regulators of energy metabolism. Curr Opin Endocrinol Diabetes Obes. 2011; 18(1): 56-60.
108. Levkovitz Y, Ben-Shushan G, Hershkovitz A, et al., Antidepressants induce cellular insulin resistance by activation of IRS-1 kinases. Mol Cell Neurosci. 2007; 36(3): 305-312.
109. Shimano H. SREBPs: physiology and pathophysiology of the SREBP family. FEBS J. 2009; 276(3): 616-621.
110. Hinze-Selch D, Schuld A, Kraus T, et al. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology. 2000; 23(1): 13-19.
111. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med. 1999. 245(6): 621-625.
112. Buergi S, Baltensperger K, Honegger UE. Antidepressant-induced switch of beta 1-adrenoceptor trafficking as a mechanism for drug action. J Biol Chem. 2003; 278(2): 1044-1052.
113. WHO, http://www.who.int/mediacentre/factsheets/fs312/en/index.html. 2011.
114. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011; 34 Suppl 1: S62-69.
115. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world--a growing challenge. N Engl J Med. 2007; 356(3): 213-215.